- Home
- BIIB vs CYBR Comparison
BIIB vs CYBR Comparison
Compare BIIB & CYBR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BIIB
- CYBR
- Stock Information
- Founded
- BIIB 1978
- CYBR 1999
- Country
- BIIB United States
- CYBR Israel
- Employees
- BIIB N/A
- CYBR N/A
- Industry
- BIIB Biotechnology: Pharmaceutical Preparations
- CYBR Computer Software: Prepackaged Software
- Sector
- BIIB Health Care
- CYBR Technology
- Exchange
- BIIB Nasdaq
- CYBR Nasdaq
- Market Cap
- BIIB 24.2B
- CYBR 24.0B
- IPO Year
- BIIB 1991
- CYBR 2014
- Fundamental
- Price
- BIIB $175.74
- CYBR $441.00
- Analyst Decision
- BIIB Buy
- CYBR Buy
- Analyst Count
- BIIB 23
- CYBR 31
- Target Price
- BIIB $176.48
- CYBR $453.23
- AVG Volume (30 Days)
- BIIB 2.0M
- CYBR 450.0K
- Earning Date
- BIIB 10-30-2025
- CYBR 11-06-2025
- Dividend Yield
- BIIB N/A
- CYBR N/A
- EPS Growth
- BIIB N/A
- CYBR N/A
- EPS
- BIIB 10.97
- CYBR N/A
- Revenue
- BIIB $10,065,900,000.00
- CYBR $1,302,851,000.00
- Revenue This Year
- BIIB $2.97
- CYBR $35.70
- Revenue Next Year
- BIIB N/A
- CYBR $19.22
- P/E Ratio
- BIIB $15.97
- CYBR N/A
- Revenue Growth
- BIIB 4.77
- CYBR 43.26
- 52 Week Low
- BIIB $110.04
- CYBR $288.63
- 52 Week High
- BIIB $176.02
- CYBR $526.19
- Technical
- Relative Strength Index (RSI)
- BIIB 76.31
- CYBR 24.11
- Support Level
- BIIB $165.75
- CYBR $473.27
- Resistance Level
- BIIB $170.78
- CYBR $520.47
- Average True Range (ATR)
- BIIB 5.16
- CYBR 13.96
- MACD
- BIIB 1.34
- CYBR -8.00
- Stochastic Oscillator
- BIIB 98.74
- CYBR 8.78
About BIIB Biogen Inc.
Biogen is an established biopharmaceutical company focused on treatments for neurological diseases and rare diseases. Its declining multiple sclerosis franchise is its largest revenue generator and contributed 45% of total revenue in 2024. Biogen also generates significant revenue from its CD20 collaboration agreements with Roche (18% of total in 2024), which includes oncology drugs Rituxan and Gazyva and multiple sclerosis drug Ocrevus. Biogen's newer franchises include Spinraza (spinal muscular atrophy, with partner Ionis), Leqembi (Alzheimer's disease, collabroation revenue from its partner Eisai), Skyclarys (Friedreich's ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (amyotrophic lateral sclerosis, Ionis).
About CYBR CyberArk Software Ltd.
CyberArk is a cybersecurity vendor focused on the identity market. The company's core privileged access management offering is a market leader in that subsegment, with more than half of the Fortune 500 as CyberArk customers. The identity security vendor was founded in 1999 and has around 9,000 customers across various industries. While CyberArk historically sold its security solutions primarily via on-premises licenses, over the past few years it has transitioned to a subscription recurring-revenue model.